P496 Feasibility and safety of single incision laparoscopic surgery for patients with complex Crohn’s disease
ECCO'20 Vienna
2020
P498 Loss of response of anti-TNF in Crohn’s disease patients single-centre experience
ECCO'20 Vienna
2020
P499 Objectively assessed disease activity during ustekinumab treatment in a nationwide real-life Crohn’s disease cohort
ECCO'20 Vienna
2020
P503 Changes in clinical use of vedolizumab are driven by lower drug costs and are associated with better outcomes: a real-life single-centre Spanish experience
ECCO'20 Vienna
2020
P504 Remote cannabis-therapy management platform for IBD patients: performance assessment
ECCO'20 Vienna
2020
P506 Increased risk of anti-drug antibodies to a second anti-TNF in patients who developed antibodies to the first anti-TNF
ECCO'20 Vienna
2020
P509 Vedolizumab levels in breast milk: Results from a prospective, postmarketing, milk-only lactation study in nursing mothers with inflammatory bowel disease
ECCO'20 Vienna
2020
P510 Dose escalation of subcutaneous vedolizumab in patients with ulcerative colitis: A post hoc analysis of the VISIBLE trial data
ECCO'20 Vienna
2020
P511 Association of ustekinumab serum concentrations and clinical outcomes: results from the mUST-DECIDE trial
ECCO'20 Vienna
2020
P512 Efficacy of tofacitinib for the treatment of moderate-to-severe ulcerative colitis: real-world data
ECCO'20 Vienna
2020